구조모아 (StructureMoa)항암 chemical structure spider web
방문프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Blenrep (belantamab mafodotin) |
Overview Company | GSK |
Overview Modality | ADC |
Overview Target | BCMA |
Overview Indication | Multiple myeloma |
Overview Phase | APPROVED |
Overview Status | DISCONTINUED |
Overview Content status | Curated Core |
Overview Data Confidence | Data Confidence · High |
Overview Development Signal | Development Signal · Established |
Overview Approval status | FDA approved |
Positioning Key differentiator | BCMA-targeted ADC with ocular AEs |
Positioning Known limitation | bypass this immune effector cell dependence, we developed a novel strategy using antibody-drug conjugates (ADCs) |
Technology Payload | MMAF |
Technology Linker | Non-cleavable |
MoA Mechanism | Belantamab mafodotin binds BCMA on plasma cells; afucosylated Fc enhances immune engagement while MMAF (microtubule inhibitor) payload is internalized and causes cell death. |
MoA Biomarker | BCMA expression on myeloma cells. |
PK/PD Half-life | 16.8 h |
PK/PD Species | Cynomolgus monkey, Human, M-protein, corneal microcysts on ophthalmic exam |
PK/PD Animal (cat.) | Human, NHP |
PK/PD Experiment | Pd |
Toxicology Species | Cynomolgus monkey, Mouse, Rat, Human |
Toxicology Animal (cat.) | Human |
Toxicology Major finding | Ocular toxicity (keratopathy, blurred vision) in majority of patients; thrombocytopenia and infusion reactions. |
Clinical Safety signal | Ocular toxicity (keratopathy, blurred vision) in majority of patients; thrombocytopenia and infusion reactions. |
Clinical Selected reported efficacy | ORR 6% |
Clinical Reported ORR | 6% |
Clinical Reported PFS | 8.4 |
Clinical Reported OS | 19 |
Clinical Result source | ClinicalTrials.gov NCT05986682 |
Clinical Program phase | APPROVED |
Clinical Trial activity | No active/completed counts |
Clinical Trial ref | NCT05986682 |
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Blenrep (belantamab mafodotin) |
Overview Company | GSK |
Overview Modality | ADC |
Overview Target | BCMA |
Overview Indication | Multiple myeloma |
Overview Phase | APPROVED |
Overview Status | DISCONTINUED |
Overview Content status | Curated Core |
Overview Data Confidence | Data Confidence · High |
Overview Development Signal | Development Signal · Established |
Overview Approval status | FDA approved |
Positioning Key differentiator | BCMA-targeted ADC with ocular AEs |
Positioning Known limitation | bypass this immune effector cell dependence, we developed a novel strategy using antibody-drug conjugates (ADCs) |
Technology Payload | MMAF |
Technology Linker | Non-cleavable |
MoA Mechanism | Belantamab mafodotin binds BCMA on plasma cells; afucosylated Fc enhances immune engagement while MMAF (microtubule inhibitor) payload is internalized and causes cell death. |
MoA Biomarker | BCMA expression on myeloma cells. |
PK/PD Half-life | 16.8 h |
PK/PD Species | Cynomolgus monkey, Human, M-protein, corneal microcysts on ophthalmic exam |
PK/PD Animal (cat.) | Human, NHP |
PK/PD Experiment | Pd |
Toxicology Species | Cynomolgus monkey, Mouse, Rat, Human |
Toxicology Animal (cat.) | Human |
Toxicology Major finding | Ocular toxicity (keratopathy, blurred vision) in majority of patients; thrombocytopenia and infusion reactions. |
Clinical Safety signal | Ocular toxicity (keratopathy, blurred vision) in majority of patients; thrombocytopenia and infusion reactions. |
Clinical Selected reported efficacy | ORR 6% |
Clinical Reported ORR | 6% |
Clinical Reported PFS | 8.4 |
Clinical Reported OS | 19 |
Clinical Result source | ClinicalTrials.gov NCT05986682 |
Clinical Program phase | APPROVED |
Clinical Trial activity | No active/completed counts |
Clinical Trial ref | NCT05986682 |
추천 비교
추천 비교